FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285403583> ?p ?o ?g. }

• W4285403583 endingPage "155.e1" @default.
• W4285403583 startingPage "145" @default.
• W4285403583 abstract "Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ILLUMINATE-C evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with PH1 and advanced kidney disease.Phase 3, open-label, single-arm trial.Multinational study; enrolled patients with PH1 of all ages, estimated glomerular filtration rate ≤45 mL/min/1.73 m2 (if age ≥12 months) or increased serum creatinine level (if age <12 months), and POx ≥20 μmol/L at screening, including patients with or without systemic oxalosis.Lumasiran administered subcutaneously; 3 monthly doses followed by monthly or quarterly weight-based dosing.Primary end point: percent change in POx from baseline to month 6 (cohort A; not receiving hemodialysis at enrollment) and percent change in predialysis POx from baseline to month 6 (cohort B; receiving hemodialysis at enrollment). Pharmacodynamic secondary end points: percent change in POx area under the curve between dialysis sessions (cohort B only); absolute change in POx; percent and absolute change in spot urinary oxalate-creatinine ratio; and 24-hour urinary oxalate adjusted for body surface area.All patients (N = 21; 43% female; 76% White) completed the 6-month primary analysis period. Median age at consent was 8 (range, 0-59) years. For the primary end point, least-squares mean reductions in POx were 33.3% (95% CI, -15.2% to 81.8%) in cohort A (n = 6) and 42.4% (95% CI, 34.2%-50.7%) in cohort B (n = 15). Improvements were also observed in all pharmacodynamic secondary end points. Most adverse events were mild or moderate. No patient discontinued treatment or withdrew from the study. The most commonly reported lumasiran-related adverse events were injection-site reactions, all of which were mild and transient.Single-arm study without placebo control.Lumasiran resulted in substantial reductions in POx with acceptable safety in patients with PH1 who have advanced kidney disease, supporting its efficacy and safety in this patient population.Alnylam Pharmaceuticals.Registered at ClinicalTrials.gov with study number NCT04152200 and at EudraCT with study number 2019-001346-17.Primary hyperoxaluria type 1 (PH1) is a rare genetic disease characterized by excessive hepatic oxalate production that frequently causes kidney failure. Lumasiran is an RNA interference therapeutic that is administered subcutaneously for the treatment of PH1. Lumasiran has been shown to reduce oxalate levels in the urine and plasma of patients with PH1 who have relatively preserved kidney function. In the ILLUMINATE-C study, the efficacy and safety of lumasiran were evaluated in patients with PH1 and advanced kidney disease, including a cohort of patients undergoing hemodialysis. During the 6-month primary analysis period, lumasiran resulted in substantial reductions in plasma oxalate with acceptable safety in patients with PH1 complicated by advanced kidney disease." @default.
• W4285403583 created "2022-07-14" @default.
• W4285403583 creator A5005896657 @default.
• W4285403583 creator A5007565150 @default.
• W4285403583 creator A5016632736 @default.
• W4285403583 creator A5039956174 @default.
• W4285403583 creator A5042385774 @default.
• W4285403583 creator A5048525391 @default.
• W4285403583 creator A5052121446 @default.
• W4285403583 creator A5054854271 @default.
• W4285403583 creator A5059893404 @default.
• W4285403583 creator A5061479404 @default.
• W4285403583 creator A5065997346 @default.
• W4285403583 creator A5070639365 @default.
• W4285403583 creator A5072061575 @default.
• W4285403583 creator A5073977366 @default.
• W4285403583 creator A5086099648 @default.
• W4285403583 creator A5087268876 @default.
• W4285403583 creator A5088563796 @default.
• W4285403583 creator A5089922351 @default.
• W4285403583 creator A5090129123 @default.
• W4285403583 date "2023-02-01" @default.
• W4285403583 modified "2023-09-30" @default.
• W4285403583 title "Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial" @default.
• W4285403583 cites W1759763432 @default.
• W4285403583 cites W1785708344 @default.
• W4285403583 cites W1963912010 @default.
• W4285403583 cites W1967634723 @default.
• W4285403583 cites W1976817693 @default.
• W4285403583 cites W1991573754 @default.
• W4285403583 cites W1997621193 @default.
• W4285403583 cites W2012590554 @default.
• W4285403583 cites W2058037274 @default.
• W4285403583 cites W2062999160 @default.
• W4285403583 cites W2069662336 @default.
• W4285403583 cites W2075121105 @default.
• W4285403583 cites W2092417370 @default.
• W4285403583 cites W2106268365 @default.
• W4285403583 cites W2106951882 @default.
• W4285403583 cites W2109644074 @default.
• W4285403583 cites W2122855609 @default.
• W4285403583 cites W2136057046 @default.
• W4285403583 cites W2496344419 @default.
• W4285403583 cites W2740296225 @default.
• W4285403583 cites W3010992580 @default.
• W4285403583 cites W3012340007 @default.
• W4285403583 cites W3012630306 @default.
• W4285403583 cites W3015680166 @default.
• W4285403583 cites W3015820982 @default.
• W4285403583 cites W3027275921 @default.
• W4285403583 cites W3028607796 @default.
• W4285403583 cites W3088623630 @default.
• W4285403583 cites W3125911222 @default.
• W4285403583 cites W3137849571 @default.
• W4285403583 cites W3151149834 @default.
• W4285403583 cites W3162171920 @default.
• W4285403583 cites W3180537911 @default.
• W4285403583 cites W4200495683 @default.
• W4285403583 cites W4236938577 @default.
• W4285403583 doi "https://doi.org/10.1053/j.ajkd.2022.05.012" @default.
• W4285403583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35843439" @default.
• W4285403583 hasPublicationYear "2023" @default.
• W4285403583 type Work @default.
• W4285403583 citedByCount "12" @default.
• W4285403583 countsByYear W42854035832022 @default.
• W4285403583 countsByYear W42854035832023 @default.
• W4285403583 crossrefType "journal-article" @default.
• W4285403583 hasAuthorship W4285403583A5005896657 @default.
• W4285403583 hasAuthorship W4285403583A5007565150 @default.
• W4285403583 hasAuthorship W4285403583A5016632736 @default.
• W4285403583 hasAuthorship W4285403583A5039956174 @default.
• W4285403583 hasAuthorship W4285403583A5042385774 @default.
• W4285403583 hasAuthorship W4285403583A5048525391 @default.
• W4285403583 hasAuthorship W4285403583A5052121446 @default.
• W4285403583 hasAuthorship W4285403583A5054854271 @default.
• W4285403583 hasAuthorship W4285403583A5059893404 @default.
• W4285403583 hasAuthorship W4285403583A5061479404 @default.
• W4285403583 hasAuthorship W4285403583A5065997346 @default.
• W4285403583 hasAuthorship W4285403583A5070639365 @default.
• W4285403583 hasAuthorship W4285403583A5072061575 @default.
• W4285403583 hasAuthorship W4285403583A5073977366 @default.
• W4285403583 hasAuthorship W4285403583A5086099648 @default.
• W4285403583 hasAuthorship W4285403583A5087268876 @default.
• W4285403583 hasAuthorship W4285403583A5088563796 @default.
• W4285403583 hasAuthorship W4285403583A5089922351 @default.
• W4285403583 hasAuthorship W4285403583A5090129123 @default.
• W4285403583 hasBestOaLocation W42854035831 @default.
• W4285403583 hasConcept C111113717 @default.
• W4285403583 hasConcept C112705442 @default.
• W4285403583 hasConcept C126322002 @default.
• W4285403583 hasConcept C126894567 @default.
• W4285403583 hasConcept C141071460 @default.
• W4285403583 hasConcept C159641895 @default.
• W4285403583 hasConcept C203092338 @default.
• W4285403583 hasConcept C2777288759 @default.
• W4285403583 hasConcept C2778063415 @default.
• W4285403583 hasConcept C2778653478 @default.
• W4285403583 hasConcept C2779978075 @default.

• next